Bacterial translocation reduction

“Bacterial translocation reduction” refers to therapeutic strategies or biological mechanisms aimed at preventing the passage of viable bacteria or their products from the gut lumen across the intestinal mucosa into systemic tissues. This outcome is relevant for conditions marked by intestinal barrier dysfunction, such as sepsis, cirrhosis, critical illness, and certain autoimmune and metabolic diseases. Clinical and experimental approaches for reducing bacterial translocation include dietary manipulation (fiber, amino acids), selective digestive decontamination with antibiotics, enhancement of epithelial tight junctions, modulation of gut microbiota (probiotics, FMT), and pharmacological reduction of inflammatory or oxidative injury to the barrier. The process is critical in limiting the risks of systemic infection, chronic inflammation, and organ dysfunction precipitated by gut-derived microbial products or viable bacteria.

Other names

Bacterial translocation preventionReduction of bacterial translocationPrevention of gut-derived bacterial translocationInhibition of bacterial translocation

Maintenance/enhancement of tight junction (TJ) proteins to prevent paracellular translocation of bacteria; Alteration of gut microbiota composition to reduce pathogenic species and promote commensals; Reduction of oxidative and inflammatory injury to epithelial barrier (e.g., xanthine oxidase inhibition); Direct bactericidal and immunomodulatory effects (macrolides, SDD antibiotics); Replenishment of healthy microbiota and restoration of barrier functions (FMT)